Name

Amanta

Legal name

Amanta Healthcare Limited

Website

https://amanta.co.in

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing: B2B contract manufacturing services for pharmaceutical clients, leveraging BFS and ISBM aseptic platforms to produce sterile dosage forms and IV fluid containers under client/supply agreements. Revenue is order-driven and tied to long-term supply contracts.
2. Branded & Generic Sterile Dosage Product Sales: Sale of proprietary branded sterile dosage products (e.g., SteriPort IV containers, Aerovein IV sets, Steriport Total) and sterile liquid dosage formulations through domestic and international distribution/marketing networks. FY26 revenue from operations: ₹28,767.67 lakhs.

Pricing tiers

Go-to-market motion2 records

Core offering

Amanta Healthcare manufactures and markets sterile liquid parenteral pharmaceutical products using Aseptic Blow-Fill-Seal (BFS) and Injection Stretch Blow Moulding (ISBM) technologies. The portfolio spans large-volume IV fluids, ophthalmic solutions, respiratory nebulization products, anti-infective infusions, sterile diluents, small-volume injectables, OTC eye-care products, and IV administration sets, sold under proprietary brands such as SteriPort, SteriPort Total, Aerovein, Nuvera, and FlowVein. The company also provides B2B contract manufacturing and formulation development services to major pharmaceutical firms in India and abroad.

Product overview

Amanta Healthcare operates a single integrated sterile liquid parenteral manufacturing and marketing platform anchored in Aseptic Blow-Fill-Seal (BFS) and Injection Stretch Blow Moulding (ISBM) technologies at its ISO- and cGMP-compliant Kheda (Gujarat) facility, with an additional Goa site. The platform delivers a comprehensive therapeutic range — Respiratory, Ophthalmics, Fluid Therapy, Anti-Infectives, Diluents, Injectables, Medical Consumables, and OTC products — in pack sizes from 2 ml to 1000 ml. Its three flagship innovations are the SteriPort IV fluid container (first-in-India RCPP/ISBM container), the SteriPort Total next-generation self-collapsible IV bottle, and the Aerovein vented IV administration set; the medical consumables line is further extended by the Nuvera and Flowvein IV sets. Two Fluid Therapy sub-lines — the FFS/BFS large volume parenterals and the SteriPort Range — operationalize the IV fluid offering. Product Partnering (contract manufacturing and formulation development) rounds out the business, serving both domestic and 77+ international markets.

Differentiator

Problem solved

Functional benefit

Brands

• SteriPort: Revolutionary IV fluid container developed using ISBM process with random copolymer polypropylene; first of its kind in India, offering 121°C sterilization and two-port closure system.
• SteriPort Total
• Aerovein
• Nuvera
• FlowVein

Products and services

• SteriPort IV Fluid Container First-in-India IV fluid container manufactured from Random Copolymer Polypropylene (RCPP) using the Injection Stretch Blow Moulding (ISBM) process; offers sterilization at 121°C, a tamper-evident two-port closure, 100% transparency for visual inspection, and eliminates leakage associated with conventional nipple-head BFS (FFS) containers. Used by hospitals and healthcare professionals for sterile large-volume parenteral administration.
• SteriPort Total IV Fluid Bottle Next-generation IV fluid bottle positioned as the successor to SteriPort, with total collapsibility, sterility at 121°C, adequate headspace for admixing, convenient visual inspection, tamper-evident closure, and onco-drug compatibility. Used across both the Formulation range (e.g., Febramol, Zolid IV, Levotrat IV) and the Fluid Therapy range (e.g., Dextrose, Normal Saline, Ringer Lactate, Electrolyte P).
• Aerovein Vented IV Administration Set Vented IV set with Air Stop (hydrophilic 15µ filter that eliminates air embolism) and Prime Stop (keeps a closed system and sterility up to Point of Administration); includes a 0.2µ air-vent filter, DEHP-free 180cm kink-resistant IV tube, advance roller clamp for flow control, Rotating Luer Lock (ROLL), spike notch for safe disposal, and a tube dock for standby mode.
• Nuvera IV Administration Set IV administration set branded as 'Adding Ease(in) fusion'; features Prime Stop (convenient priming, prevents spillage, maintains sterility), Rotating Luer Lock (ease of use, less IV-site disturbance, pain-free connectivity, hassle-free add-on medication, reduced risk of Phlebitis & Cellulitis), and a large chamber for effortless priming and visual inspection.
• FlowVein IV Administration Set IV administration set branded as 'Care with comfort'; features a Luer Lock for needle-free operation, a large chamber for visual inspection and desired flow rate, and a Y-Shield for safe and convenient add-on medication with reduced risk of Phlebitis and Cellulitis.
• Respiratory Range (Nebulization Solutions) Sterile nebulization solutions for respiratory conditions, including Salbutamol & Ipratropium Bromide Respiratory Solution 2.5mg+500mcg (2.5 ml), Salbutamol Respiratory Solution 2.5mg, Budesonide Nebuliser Suspension (2 ml), Levosalbutamol Inhalation Solution, and Levosalbutamol & Ipratropium Bromide Respiratory Solution 1.25mg+0.5mg (2.5 ml).
• Ophthalmics Range Comprehensive portfolio of sterile therapeutic ophthalmic solutions for ocular problems, including Gentamycin & Dexamethasone Eye/Ear Drops, Gentamycin BP, Ofloxacin USP, Moxifloxacin Eye Drops USP, Tobramycin & Dexamethasone, Tobramycin Eye Drops USP, Timolol Maleate Eye Drops BP, Ciprofloxacin Eye Drops USP, and Balance Salt Solution (500 ml).
• Fluid Therapy (IV Fluids) Extensive range of sterile IV solutions in pack sizes from 100 ml to 1000 ml, including essential rehydration fluids (Sodium Chloride, Glucose) and advanced premixed formulations (Lactated Potassic Saline). Delivered through two sub-lines: SteriPort/SteriPort Total containers and conventional FFS containers, covering Ringer Lactate, Electrolyte P/M, Dextrose 5/10/20/25%, Normal Saline 0.9%/0.45%, DNS, Mannitol 20%, and Hypertonic Sodium Chloride 3%.
• Anti-Infectives Range Sterile therapeutic solutions to prevent and treat a broad spectrum of infections: Metronidazole Injection (0.5% w/v, 100 ml), Ofloxacin Infusion (0.2% w/v), Tinidazole Infusion 200mg/100ml (400 ml), Linezolid I.V. Injection 200mg/100ml (300 ml), Levofloxacin Infusion 500mg/100ml, Paracetamol Infusion 10 mg/ml, Moxifloxacin IV Infusion 400 mg/100 ml, Fluconazole Infusion 200mg/100ml, Ciprofloxacin Injection 0.2% w/v, Mannitol Injection 20% w/v, and Ornidazole 500mg/100ml.
• Diluents Range Sterile diluents essential for safe drug reconstitution and infusion: Sterile Water for Injection BP/USP (2 ml / 5 ml / 10 ml / 20 ml) and Normal Saline BP 0.9% (3.5 ml).
• Injectables Range Ready-to-use sterile injectable medicines for hospital and emergency care: Magnesium Sulfate Injection USP (50% w/v), Dextrose Injection BP 40% w/v (20 ml), Lignocaine/Liodocaine Injection BP 1% w/v (3.5 ml), and Potassium Chloride Injection 15% w/v.
• OTC Range Trusted over-the-counter products supporting everyday health and wellness: Sodium Chloride 0.9% Eye Wash & Wound Irrigation Solution (5 ml / 20 ml), Carboxymethyl Cellulose Sodium Eye Drops 0.5% w/v (10 ml), Hypromellose Eye Drops 0.5% w/v, and Sodium Hyaluronate Eye Drops 0.3% w/v.
• FFS (Form Fill Seal) Large Volume Parenterals Conventional Aseptic Blow-Fill-Seal (BFS) large volume parenteral range covering 0.9% Normal Saline (100/250/500/1000 ml), 0.45% Normal Saline, Dextrose 5% (250/500/1000 ml), Dextrose 5% with 0.9% Normal Saline, Dextrose 5% with 0.45% Normal Saline (500/1000 ml), Dextrose 10%, Dextrose 25% (100/500 ml), Ringer Lactate, Electrolytes P (100/250/500 ml), Electrolytes M, Dextrose 20% with multiple electrolytes (veterinary), and Sterile Water for Injection.
• SteriPort Range (SteriPort-Container IV Fluids) SteriPort-container product line available in 100/250/500/1000 ml formats, plus specialty 100/500 ml options, including Ringer Lactate, Electrolytes P (Sterilyte P, 250/500 ml), Electrolytes M (Sterilyte M), Sodium Chloride Hypertonic Injection 3.0% w/v, and Mannitol Injection 20% w/v.
• Product Partnering (Contract Manufacturing & Formulation Development) Contract manufacturing and formulation development service for major pharma companies in India and abroad, including regulatory services (dossier filing for semi-regulated and advanced markets, FDA liaison, query handling) and F&D capabilities for 'difficult-to-make' sterile liquids across ophthalmics, single-dose injectables, respiratory solutions, fluid therapy, and irrigation solutions — taking projects from lab-scale to commercial production.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves7 records

Expansion highlights3 records

Broad incumbents

• B. Braun Melsungen: Global medical technology and pharmaceutical company with a leading IV fluids / large-volume parenteral franchise. Comparable to Amanta as a vertically integrated manufacturer of sterile IV solutions and infusion accessories serving hospitals worldwide, though at much larger scale.
• Baxter International: Global leader in IV solutions, IV administration sets, and sterile injectable pharmaceuticals. Closest large-cap analog to Amanta's IV fluids plus medical consumables platform across Fluid Therapy and Aerovein/Nuvera/Flowvein sets.
• Fresenius Kabi: Specialty pharma arm of Fresenius focused on sterile injectable drugs, IV fluids, and medical devices. Direct overlap with Amanta's sterile liquid parenterals and IV container portfolio, including presence in the Indian market.
• Becton, Dickinson and Company (BD): Global medical device leader with a large IV administration sets and infusion therapy portfolio. Comparable to Amanta's medical consumables line (Aerovein, Nuvera, Flowvein).
• Terumo Corporation: Japanese medical device maker with a significant IV infusion systems business, including IV administration sets and infusion containers. Comparable to Amanta's IV sets and BFS container offerings.
• Nipro Corporation: Japanese medical device and pharmaceutical company producing IV containers, dialyzers, and injection-related products. Comparable to Amanta's sterile container platform and IV therapy focus.
• Pfizer CentreOne (Hospira heritage): Global sterile injectable contract manufacturing organization descended from Hospira. Comparable to Amanta's Product Partnering / B2B contract manufacturing business for ophthalmics, respiratory, and sterile liquids.

Direct peers

• Claris Lifesciences (now Bausch + Lomb / Claris Injectables): India-headquartered sterile injectable manufacturer historically focused on large-volume parenterals and small-volume injectables. The closest India-domestic direct peer to Amanta in contract manufacturing and branded sterile injectables.
• Aculife Healthcare (Nirma Group): Major Indian manufacturer of large-volume parenterals (IV fluids) and sterile injectables. Direct India competitor to Amanta in the FFS/BFS IV fluid and electrolyte segment.

Regional players

• Aurobindo Pharma: Large Indian generics and sterile injectables player with global exports. Regional peer in the Indian sterile injectable landscape that competes for similar contract manufacturing and tender business as Amanta.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amanta-healthcare-ltd-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amanta